Coronary sinus-based percutaneous annuloplasty as treatment for functional mitral regurgitation: the TITAN II trial.
Janusz Lipiecki, Tomasz Siminiak, Horst Sievert...
https://pubmed.ncbi.nlm.nih.gov/27493761/Actively Recruiting
Led by Cardiac Dimensions, Inc. · Updated on 2026-04-13
300
Participants Needed
92
Research Sites
208 weeks
Total Duration
Researchers are evaluating the safety and effectiveness of the Carillon Mitral Contour System CMCS in treating patients with heart failure who also have functional mitral regurgitation FMR. This prospective, randomized, double-blinded, sham-controlled trial aims to better understand how this device may impact heart function and symptoms in people with this condition. Participants will be randomly assigned to one of two groups one group will receive the Carillon implant along with guideline-directed heart failure medications, while the other group will receive only the heart failure medications and a sham procedure to preserve blinding. Before randomization, patients will undergo specific heart imaging tests and evaluations to determine eligibility and suitability for the device placement. After the procedure, participants will have follow-up visits at 1, 6, 12, 18, and 24 months to monitor safety and heart function. After 24 months, all participants will be informed of their group assignment and followed annually for an additional three years. During the study, researchers will assess various health outcomes including freedom from major adverse events at 12 months and clinical improvement at 24 months. Additional measures will include changes in heart valve function, heart size, walking ability, heart failure symptoms, hospitalizations, and quality of life. Participants will have regular heart imaging, clinical evaluations, and questionnaires to track these outcomes. The total participation time may extend up to five years with long-term monitoring to better understand the devices impact over time.
CONDITIONS
The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR
H
Hank Hauser
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Cardiac Dimensions, Inc.
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Carillon device group | Guideline‑directed medical therapy group | Guideline‑directed medical therapy (external context) |
|---|---|---|---|
| What it is | A transcatheter device implanted via the coronary vein to reshape the mitral valve annulus and reduce functional mitral regurgitation | Optimization of guideline‑directed heart failure medication per ACC/AHA protocols | Standard medical therapy for functional mitral regurgitation in heart failure per guidelines |
| Role in trial | Investigational treatment arm | Active comparator arm receiving guideline‑directed therapy | Represents how patients are treated in routine clinical practice without device |
| Primary use | To treat functional mitral regurgitation by reducing annular dilation | To manage heart failure symptoms and underlying ventricular remodeling | To manage symptoms and mitigate progression of FMR via optimized heart failure therapy |
| How it is given or performed | Percutaneous implantation of a tensioned device in the coronary sinus via venous access | Medication titration per guideline protocols | Medical therapy administered according to heart failure guideline protocols (e.g., ACE‑I, beta‑blockers, etc.) |
| Evidence status | Evidence is emerging from device‑specific trials (e.g., TITAN, TITAN II) showing technical feasibility and early efficacy | Long‑standing evidence supports guideline‑directed medical therapy for symptom management and remodeling in FMR | Strong guideline and literature support GDMT as foundation of FMR management |
| Important risks | Risks related to device implantation in coronary sinus; specific safety profile under evaluation | Medication side‑effects per individual drug profile; known tolerability issues | Medication adverse effects are well characterized across guideline‑recommended agents |
| Important limitations | Evidence is limited to early phase trials and registries; long‑term outcomes and broader applicability under study | GDMT may not fully reverse severe mitral regurgitation or address mechanical annular dilation | Medical therapy alone may be insufficient in advanced FMR where structural correction is needed |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening and enrollment visit
Duration - Procedure day
Participants randomized to the Intervention group undergo the Carillon implant procedure. Participants in the Control group have a similar index procedure without implant placement to maintain blinding.
1 procedure visit (in-person)
Duration - 24 months
After discharge, participants are followed up to assess long-term safety and clinical status.
5 visits at 1, 6, 12, 18, and 24 months post-randomization
Duration - 3 years
Participants are followed annually with contact and echocardiogram to monitor ongoing status.
Annual visits for 3 years after 24-month evaluation
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Janusz Lipiecki, Tomasz Siminiak, Horst Sievert...
https://pubmed.ncbi.nlm.nih.gov/27493761/Joachim Schofer, Tomasz Siminiak, Michael Haude...
https://pubmed.ncbi.nlm.nih.gov/19597051/Tomasz Siminiak, Justina C Wu, Michael Haude...
https://pubmed.ncbi.nlm.nih.gov/22613584/Cardiac Dimensions, Inc.
Lead Sponsor